Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by forhandlarenon Jul 06, 2023 6:02pm
179 Views
Post# 35530012

RE:Crappy Stock Price

RE:Crappy Stock PriceI share the frustration over such a low share price and management failure to provide the market with information good enough for analysts needs.

However, I don't really understand what difference the conference should have made short term for the share price? I think it's a mistake to read to much in it.

Nevertheless, they missed out on the obvious opportunity to put forward Atheln and let them communicate the vibe of the conference and great interest from deep pockets - THAT would've at least supported the share price on the same level as pre-conference - BECAUSE company valuation reflects dreams and expectations of future revenue, which is next to none today.

They simply doesn't understand the basics of marketing and shareholder care. It's so painfully obvious looking at the conference photo of Howard walking down an empty corridor...

I'm actually confident that they have something of value thanks to excellent science, but maybe Howard is too proud to let Atheln steer the wheel and that's not very favourable short term.
<< Previous
Bullboard Posts
Next >>